Immutep Ltd at Jefferies Healthcare Conference Transcript
Good morning, everyone. Welcome to day two of the fabulous Jefferies US Healthcare Conference. My name is Dave Stanton, and I'm part of the Australian healthcare research team. We're delighted to be hosting Marc Voigt, CEO of Immutep today.
He's got a presentation for us and then -- and at the end, we'll hopefully have a bit of time for questions. But Marc, thank you very much and over to you.
Yeah. Thank you, Dave, and thank you all for attending. My forward-looking statement. So few key characteristics regarding Immutep. First of all, we are the only LAG-3 pure play and I believe it's fair to say that we have been pioneering the LAG-3 space, which is obviously a very important immune checkpoint.
We are clinical stage company. We work together with different partners in the industry. Few of the logos you see there. And we are also globally active. We have our headquarter in Sydney, Australia at Australia Square and then subsidiaries in Germany and France and in the United
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |